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Introduction {#sec001}
============

Traditional Chinese medicine prescriptions (TCMPs), which are combinations of several medicinal herbs, have been widely employed for thousands of years in China and other Asian countries. In clinical practice, TCMPs often exhibit significant advantages of low therapeutic risk and remarkable effect for some chronic, multifactorial and systemic diseases \[[@pone.0121031.ref001]--[@pone.0121031.ref004]\]. However, due to the extreme complexities of multiple TCMP components, revealing their pharmacological material basis and mechanism of action remains challenging. Consequently, an effective and reliable analytical approach for the rapid screening and identification of the multiple components contained in TCMPs is in high demand.

Currently, due to its significant advantages in analytical speed and detection sensitivity, ultra-performance liquid chromatography coupled with electrospray ionization tandem quadrupole time-of-flight mass spectrometry (UPLC-ESI-Q/TOF-MS) has become an irreplaceable technique for the on-line structural elucidation of multiple components in mixtures, especially for complex TCMs/TCMPs, biological samples and pesticide residues \[[@pone.0121031.ref005]--[@pone.0121031.ref009]\]. UPLC coupled with MS^E^ (^E^ represents collision energy) technology provides an automated strategy to decrease analysis time and maximize duty cycles by using parallel alternating scans at low collision energy in the collision cell to obtain precursor ion information or at high collision energy to obtain accurate full-scan mass fragment, precursor ion and neutral loss information. Therefore, both precursor and fragmentation data in exact mass mode were collected in a single run; this method has provided excellent chromatographic and MS efficiencies for the rapid structural elucidation of multiple constituents in complex mixtures \[[@pone.0121031.ref010]--[@pone.0121031.ref012]\]. In the present study, based on the point of view that a certain type of chemical compounds could produce identical or similar characteristic fragment ions under a suitable collision energy in their tandem mass spectra, a well-designed analytical approach that enabled rapid screening and characterization of multiple TCMP constituents was developed. By virtue of UPLC-ESI-Q/TOF-MS and optimized MS^E^ method, diagnostic fragment ions can be used as invaluable evidence for the detection of both expected and unexpected chemical constituents within TCMPs.

Re-Du-Ning injection (RDN), a traditional Chinese medicine injection (TCMI), was manufactured by Jiangsu Kanion Pharmaceutical Co. Ltd. (Lianyungang, China) and consists of three common herbs: *Lonicera japonica* Thunb. (*L*. *japonica* Thunb.; Jin-yin-hua), *Gardenia jasminoides* Ellis (*G*. *jasminoides* Ellis; Zhi-zi) and *Artemisia annua* L. (*A*. *annua* L.; Qing-hao). In China, RDN is widely used for the treatment of viral infection, such as hand-foot-mouth disease \[[@pone.0121031.ref013]--[@pone.0121031.ref014]\], influenza \[[@pone.0121031.ref015]\] and herpes angina efficacy \[[@pone.0121031.ref016]\]. Although RDN has proven to be clinically effective, the knowledge of its chemical constituents is still limited. The elucidation of the various components contained in RDN is urgently necessary and of great importance to RDN quality control and to understanding its mechanism of action.

In this paper, a robust Waters UPLC-ESI-Q/TOF-MS system and optimized MS^E^ method was utilized, employing RDN as an example for illustration. To our knowledge, this work is the first study on the chemical components contained in RDN using the methodology developed herein. As a result, a total of 90 compounds, including 45 iridoids, 21 organic acids, nine flavonoids, seven lignans, four sesquiterpenes, three coumarins and one monoterpene were identified or tentatively characterized in RDN. In addition, the source plants of these compounds were confirmed by comparing the extracted ion chromatograms (EICs) of RDN to the corresponding ingredient herbs. This work provides a certain foundation for further studies of RDN. More importantly, this novel approach is expected to be widely applied for analyzing other TCMPs and complex mixtures.

Materials and Methods {#sec002}
=====================

2.1. Chemicals and materials {#sec003}
----------------------------

*G*. *jasminoides* Ellis, *L*. *japonica* Thunb. and *A*. *annua* L. were purchased from the Ji\'an Medical Material Market (Jiangxi, China). All herbal medicines were identified by Professor Zhou Wu (Jiangsu Kanion Pharmaceutical Co. Ltd.). A voucher specimen was deposited in Jiangsu Kanion Pharmaceuticals (Lianyungang, China). The Re-Du-Ning injection (Batch number: 100906) was manufactured and supplied by Jiangsu Kanion Pharmaceutical Co. Ltd. (Lianyungang, China).

All reference standards were isolated from the RDN injection by various column chromatography techniques and were unambiguously identified by nuclear magnetic resonance (NMR) and MS methods in our laboratory.

Liquid chromatography (LC)-MS-grade acetonitrile and water were purchased from Fisher Scientific (Fair Lawn, New Jersey, USA). LC-MS-grade formic acid was obtained from Sigma-Aldrich (St. Louis, USA). The water, methanol and ethanol used for sample extraction were all of analytical grade.

2.2. Sample preparation {#sec004}
-----------------------

The RDN samples were directly evaporated with a rotary evaporator and then diluted to 10 mg/mL. Next, 2 mL of these solutions were transferred into separate clean tubes and dried under nitrogen gas at room temperature. The residues were reconstituted in 2 mL of water and then centrifuged at 10000 rpm for 10 min. Solid-phase extraction (SPE) cartridges, (Vac 3cc, 200 mg, Phenomenex strata C18-E, Torrance, CA) were preconditioned with 3 mL of methanol, followed by 3 mL of water before use. The supernatants were loaded onto the SPE cartridges and washed with 2 mL of water. The SPE cartridges were then eluted with 4 mL of methanol, and the eluents were centrifuged at 10000 rpm for 10 min. Supernatant aliquots of 2 μL were injected into the UPLC/Q-TOF-MS system for analyses.

Ingredient herbal medicine samples (*G*. *jasminoides*, 2 g; *L*. *japonica*, 2 g; *A*. *annua*, 2 g) were immersed in 20 mL of deionized water for 1 h. The solutions were then decocted by boiling 3 times (1 h each time). The extracts were diluted to generate 20 mg/mL solutions. All samples were filtered through a 0.22 μm filter membrane before UPLC-MS analyses.

2.3. UPLC-Q/TOF-MS analyses {#sec005}
---------------------------

UPLC analyses were performed using an ACQUITY UPLC system equipped with a binary solvent system, an automatic sample manger and photodiode array (PDA) detector. The chromatographic separation was performed on an Acquity UPLC BEH C18 Column (3.0 mm × 150 mm, 1.7 μm, waters, Ireland) at a temperature of 40°C. The mobile phases consisted of eluent A (0.1% formic acid in water, v/v) and eluent B (0.1% formic acid in acetonitrile, v/v). These eluents were delivered at a flow rate of 0.4 mL/min with a linear gradient program as follows: 2--5% B from 0 to 5.0 min, 5--12% B from 5.0 to 10.0 min, 12--30% B from 10.0 to 15.0 min, 30--55% B from 15.0 to 19.0 min and 55--100% B from 19.0 to 20.0 min. After maintaining 100% B for 3 min, the column was returned to its initial condition.

The UPLC system was coupled to a hybrid quadrupole, orthogonal time-of-flight (Q-TOF) tandem mass spectrometer (SYNAPT G2 HDMS, Waters, Manchester, U.K.) equipped with ESI. The operating parameters were as follows: capillary voltage of 3 kV (ESI[+]{.smallcaps}) or -2.5 kV (ESI-), sample cone voltage of 35 V, extraction cone voltage of 4 V, source temperature of 100°C, desolvation temperature of 300°C, cone gas flow of 50 L/h and desolvation gas flow of 800 L/h. In MS^E^ mode, the trap collision energy for the low-energy function was set at 5 eV, while the ramp trap collision energy for the high-energy function was set at 20--50 eV. Argon was used as the collision gas for collision-induced dissociation (CID) in MS^E^ and MS^2^ modes. To ensure mass accuracy and reproducibility, the mass spectrometer was calibrated over a range of 50--1500 Da using a solution of sodium formate. Leucine-enkephalin (*m/z* 556.2771 in positive ion mode; *m/z* 554.2615 in negative ion mode) was used as an external reference for the LockSpray and was infused at a constant flow of 5 μL/min. The data were centroided during acquisition.

Results and Discussion {#sec006}
======================

3.1. Optimization of UPLC and mass spectrometry conditions {#sec007}
----------------------------------------------------------

The MS^E^ acquisition mode required well-resolved peaks to ensure that the predominant fragments were collected from a single precursor ion. Obtaining a desirable chromatographic profile with satisfactory separation and peak shapes without excessive peak tailing was necessary. Different UPLC conditions that included both mobile phase systems (methanol-aqueous and acetonitrile-aqueous) were tested. When the mobile phase was acetonitrile-aqueous, the separation resolution was greatly improved compared to methanol-aqueous. Addition of 0.1% formic acid to the mobile phase reduced peak tailing and enhanced the resolution. Thus, an acetonitrile-aqueous solution with 0.1% formic acid was selected as the mobile phase. In addition, four analytical columns, including the Acquity BEH C18 column (3.0 mm × 150 mm, 1.7 μm), Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μm), Acquity HSS T3 column (2.1 mm × 50 mm, 1.8 μm) and Acquity Shield PR18 column (2.1 mm × 50 mm, 1.7 μm) were compared to achieve better separation performance. Unfortunately, the results of three different 50 mm columns were not satisfactory as shown in ([S1 Fig](#pone.0121031.s001){ref-type="supplementary-material"}). Then, we found that the column length could influence the separation efficiency significantly. Thus, the Acquity BEH C18 column (3.0 mm × 150 mm, 1.7 μm) was chosen for analysis in current condition. For mass spectrometry, both positive and negative ion modes were tested, and each target compound type was analyzed in a suitable ESI mode.

3.2. Establishment of the supporting database {#sec008}
---------------------------------------------

A systematic investigation of the chemical constituents in RDN was conducted. A self-built database of compounds that were isolated from three medicinal herb ingredients of RDN was established by retrieving on-line databases or Internet search engines, such as Chemical Abstracts Service (CAS) database, Massbank, Web of Science and ChemSpider. The emphasis was placed on analyzing structural characteristics and MS fragmentation behaviors, especially for diagnostic ions (characteristic fragments). As a result, 259 constituents, including iridoids, organic acids, flavonoids, sesquiterpenes, lignans and coumarins were collected. Five items, compound name, molecular formula, accurate mass, diagnostic fragment ions or neutral losses and UV absorption, were recorded.

3.3. Diagnostic ion screening using the optimized MS^E^ method {#sec009}
--------------------------------------------------------------

All chemical constituents in herbal medicine can be categorized into different families based on structural types. Thus, a certain family of compounds with identical carbon skeletons could produce similar characteristic fragment ions under CID conditions in mass spectrometry.

Accordingly, the core idea of our approach is to use the diagnostic ions as markers for target compound detection. To simultaneously generate both precursor and fragment ions using the MS^E^ method, low- and high-energy scan functions were switched rapidly and continuously for data acquisition. The high-energy scan function that is used to collect information on fragment ions is generally equivalent to a non-selective MS/MS scan. With such a function, specific diagnostic ions of diverse compounds contained in TCMPs and their precursor ions and neutral losses were simultaneously collected, providing large quantities of valuable information regarding the structural identification of chemical constituents.

In this study, the screening process of caffeoylquinic acids was considered to describe the approach in detail. Based on the aforementioned self-built database, fragment ions at *m/z* 191.0556 and *m/z* 179.0340, which can be produced from caffeoylquinic acids as common sub-structures, were selected as diagnostic ions for detecting other analogues. As shown in ([Fig 1](#pone.0121031.g001){ref-type="fig"}), the peaks that appeared in the EIC of the high-energy function of the MS^E^ mode were considered as target compounds and further characterized by accurate mass measurements, MS fragmentation analyses and reference standards. Interestingly, an unexpected compound (labeled as **35**) that possessed a novel structure with a rare caffeoylquinic ester acylated at the C-10 position of geniposide was similarly screened out. By comparison, only a few peaks could be detected in the EIC mode of the low-energy MS^E^ function. A wide range of ramped CE (20--50 eV in the present study) in the high-energy MS^E^ function will help reveal the MS fragmentation behaviors of different compounds simultaneously. Similarly, other types of analogues were rapidly screened out by our proposed approach, such as iridoids ([S2 Fig](#pone.0121031.s002){ref-type="supplementary-material"}), flavonoids ([S3 Fig](#pone.0121031.s003){ref-type="supplementary-material"}) and others.

![MS chromatograms of diagnostic ions:\
(A) EICs of diagnostic ions 179.0340 and 191.0556 in the high-energy function of MS^E^; (B) TIC of RDN in the high-energy function of MS^E^; (C) EICs of diagnostic ions 179.0340 and 191.0556 in the low-energy function of MS^E^; (D) TIC of RDN in the MS^E^ low-energy function.](pone.0121031.g001){#pone.0121031.g001}

3.4. Identification of chemical constituents in RDN {#sec010}
---------------------------------------------------

A total of 90 compounds, including 45 iridoids, 21 organic acids, nine flavonoids, seven lignans, four sesquiterpenes, three coumarins and one monoterpene were identified or tentatively characterized in RDN ([Table 1](#pone.0121031.t001){ref-type="table"}; [S4 Fig](#pone.0121031.s004){ref-type="supplementary-material"}). The herb sources of these compounds were confirmed by comparing the base peak chromatograms of RDN to a single herbal extract. The main active constituents of RDN (i.e., caffeoylquinic acids and iridoids) were rapidly screened out by UPLC-ESI/Q-TOF mass spectrometry through diagnostic ion screening with MS^E^. The remaining compounds were identified according to their accurate mass measurements within 5 ppm error, tandem MS behaviors, database-matching and reference standards. Both negative and positive ion modes were examined, and the base peak intensity (BPI) profiles of RDN and three ingredient herbs are shown in ([Fig 2](#pone.0121031.g002){ref-type="fig"}, [S5](#pone.0121031.s005){ref-type="supplementary-material"} and [S6](#pone.0121031.s006){ref-type="supplementary-material"} Figs). Recently, ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) has been widely used to characterize chemical profiling of herbal medicines and TCMPs. This method has become one of the most frequently applied approaches in the area of fast chromatographic separations \[[@pone.0121031.ref017]--[@pone.0121031.ref019]\]. High-resolution tandem mass spectrometry can provide a more specific and accurate mass as long as the co-eluting compounds possess different *m/z* values \[[@pone.0121031.ref020]\]. And the isotopic abundances and the elemental composition of fragment ions are greatly conducive to the structural elucidation of unknown compounds. However, it should be pointed out that identification of chemical components from complex TCMPs relying solely on mass spectrometry-based approaches was insufficient. As the spectral differences for some isomers are very small and they cannot be differentiated and unambiguously identified. Therefore, in present study, some reference standards isolated from the entitled injection were used to validate the elucidation of those isomers. Thus, it provides the enhanced accuracy and reliability of MS quantitative results.

![UPLC-ESI-Q-TOF-MS analysis of RDN:\
(A) UV (225 nm) chromatograph; (B) (-) ESI-MS BPI profile; (C) (+) ESI-MS BPI profile.](pone.0121031.g002){#pone.0121031.g002}
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###### Compounds identified in RDN by UPLC-ESI-Q-TOF-MS.

![](pone.0121031.t001){#pone.0121031.t001g}

  No                                        t~*R*~   Selected ion   Elemental composition   Measured mass   Calculated mass   Mass error   MS^E^ or MS^2^ fragmentation                                                               Identification                                                                                                             Source[^a^](#t001fn001){ref-type="table-fn"}
  ----------------------------------------- -------- -------------- ----------------------- --------------- ----------------- ------------ ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  1                                         6.30     \[M+Na\]^+^    C~16~H~22~O~11~         413.1056        413.1060          -1.0         251.0533, 233.0425;                                                                        deacetylasperulosidic acid                                                                                                 Gj
  2                                         6.64     \[M+Na\]^+^    C~16~H~22~O~10~         397.1111        397.1111          0.0          235.0584, 217.0475;                                                                        gardoside                                                                                                                  Gj
  3                                         7.12     \[M+Na\]^+^    C~16~H~24~O~11~         415.1216        415.1216          0.0          253.0685, 235.0581, 217.0478, 173.0579;                                                    shanzhiside                                                                                                                Gj
  4                                         7.28     \[M+Na\]^+^    C~16~H~22~O~10~         397.1111        397.1111          0.0          235.0582, 217.0477, 173.0578;                                                              geniposidic acid                                                                                                           Gj
  5                                         7.53     \[M+Na\]^+^    C~16~H~22~O~11~         413.1064        413.1060          1.0          251.0537, 233.0423, 215.0322;                                                              monotropein                                                                                                                GJ
  6                                         7.73     \[M+Na\]^+^    C~17~H~24~O~11~         427.1200        427.1216          -3.7         265.0687, 247.0583, 215.0324;                                                              deacetylasperulosidic acid methyl ester                                                                                    Gj
  7                                         7.80     \[M+Na\]^+^    C~17~H~26~O~11~         429.1363        429.1373          -2.3         267.0844, 249.0738, 217.0476;                                                              shanzhiside methyl ester                                                                                                   Gj
  8                                         7.86     \[M+Na\]^+^    C~16~H~22~O~11~         413.1073        413.1060          3.1          251.0536, 233.0422;                                                                        scandoside                                                                                                                 Gj
  9                                         8.30     \[M+Na\]^+^    C~17~H~24~O~11~         427.1218        427.1216          0.5          265.0687, 247.0583, 215.0324;                                                              gardenoside                                                                                                                Gj
  10                                        8.68     \[M+Na\]^+^    C~17~H~24~O~10~         411.1263        411.1261          1.0          249.0738, 231.0634, 199.0370;                                                              8-epi-apodantheroside                                                                                                      Gj
  11                                        9.01     \[M+Na\]^+^    C~16~H~22~O~12~         429.1025        429.1009          2.1          267.0485, 249.0378, 217.0115;                                                              8-epi-kingiside                                                                                                            Lj
  12                                        9.18     \[M+Na\]^+^    C~17~H~26~O~11~         429.1369        429.1373          -0.9         267.0846, 249.0741, 217.0479;                                                              morroniside                                                                                                                Lj
  13                                        9.42     \[M+Na\]^+^    C~16~H~22~O~11~         413.1058        413.1060          -0.5         251.0541, 233.0427;                                                                        secologanoside                                                                                                             Lj
  14[\*](#t001fn002){ref-type="table-fn"}   9.56     \[M+Na\]^+^    C~23~H~34~O~15~         573.1782        573.1795          -2.3         411.1268, 249.0740, 231.0633, 199.0372;                                                    genipin-1-β-[d]{.smallcaps}-gentiobioside                                                                                  Gj
  15                                        9.78     \[M+Na\]^+^    C~16~H~22~O~10~         397.1115        397.1111          1.0          235.0584, 217.0475, 199.0371, 173.0214,147.0056;                                           secologanic acid                                                                                                           Lj
  16                                        9.90     \[M+Na\]^+^    C~16~H~22~O~12~         429.1010        429.1009          0.1          267.0487, 249.0379, 217.0111;                                                              kingiside                                                                                                                  Lj
  17                                        10.48    \[M+Na\]^+^    C~17~H~26~O~10~         413.1429        413.1424          1.2          251.0894, 233.0788;                                                                        loganin                                                                                                                    Lj
  18[\*](#t001fn002){ref-type="table-fn"}   10.56    \[M+Na\]^+^    C~17~H~24~O~10~         411.1279        411.1267          2.9          249.0741, 209.0829, 199.0372;                                                              geniposide                                                                                                                 Gj
  19[\*](#t001fn002){ref-type="table-fn"}   10.57    \[M+H\]^+^     C~28~H~36~O~14~         597.2195        597.2183          2.7          435.1654, 417.1548, 207.0654, 175.0397;                                                    jasmigeniposide B                                                                                                          Gj
  20                                        10.81    \[M+Na\]^+^    C~16~H~22~O~9~          381.1156        381.1162          -1.6         219.0632, 201.0525, 173.0577;                                                              sweroside                                                                                                                  Lj
  21                                        11.02    \[M+Na\]^+^    C~17~H~22~O~10~         409.1100        409.1111          -2.7         247.0583, 229.0478;                                                                        methyl1-(β-[d]{.smallcaps}-glucopyranosyloxy)-7-(hydroxymethyl)-1,7a-dihydrocyclopenta\[c\]pyran-4-carboxylate             Gj
  22[\*](#t001fn002){ref-type="table-fn"}   11.10    \[M+Na\]^+^    C~25~H~28~O~12~         543.1472        543.1478          -1.1         397.1114, 235.0585, 217.0482;                                                              6′-*O*-*trans*-p-coumaroylgeniposidic acid                                                                                 Gj
  23[\*](#t001fn002){ref-type="table-fn"}   11.51    \[M+Na\]^+^    C~17~H~24~O~11~         427.1207        427.1216          -2.1         265.0674, 247.0590, 215.0326;                                                              secoxyloganin                                                                                                              Lj
  24[\*](#t001fn002){ref-type="table-fn"}   11.66    \[M+Na\]^+^    C~17~H~24~O~10~         411.1266        411.1267          -0.2         249.0741, 231.0642, 199.0374;                                                              7-epi-vogeloside                                                                                                           Lj
  25[\*](#t001fn002){ref-type="table-fn"}   11.84    \[M+Na\]^+^    C~17~H~24~O~10~         411.1265        411.1267          -0.5         249.0739, 231.0644, 199.0378;                                                              vogeloside                                                                                                                 Lj
  26[\*](#t001fn002){ref-type="table-fn"}   11.93    \[M+H\]^+^     C~25~H~33~NO~11~        524.2131        524.2132          -0.2         362.1603;                                                                                  L-phenylalanino secologanin                                                                                                Lj
  27[\*](#t001fn002){ref-type="table-fn"}   12.04    \[M+Na\]^+^    C~17~H~24~O~10~         411.1269        411.1267          0.5          249.0745, 231.0642, 199.0377;                                                              secologanin                                                                                                                Lj
  28                                        12.35    \[M+Na\]^+^    C~19~H~26~O~11~         453.1388        453.1373          3.3          411.1266, 249.0741, 217.0478;                                                              6′-*O*-acetylgeniposide                                                                                                    Gj
  29                                        13.03    \[M+H\]^+^     C~20~H~27~NO~11~        458.1682        458.1662          4.4          296.1133, 278.1029;                                                                        lonijaposide J                                                                                                             Lj
  30                                        13.11    \[M+Na\]^+^    C~18~H~26~O~11~         441.1375        441.1373          0.5          279.0844, 261.0744, 229.0472;                                                              dimethyl secologanoside                                                                                                    Lj
  31                                        13.21    \[M+Na\]^+^    C~27~H~32~O~14~         603.1688        603.1690          -0.3         422.1191, 260.0663, 242.0554;                                                              6′-*O*-*trans*-sinapoyl gardoside                                                                                          Gj
  32                                        13.72    \[M+H\]^+^     C~18~H~25~NSO~8~        416.1372        416.1379          -1.7         254.0852, 236.0746;                                                                        xylostosidine                                                                                                              Lj
  33                                        13.80    \[M+Na\]^+^    C~21~H~28~O~13~         511.1425        511.1428          -0.4         411.1254, 249.0742, 231.0712;                                                              10-*O*-succinoylgeniposide                                                                                                 Gj
  34                                        13.83    \[M+H\]^+^     C~19~H~25~NSO~10~       460.1281        460.1277          0.9          298.0751, 280.0646;                                                                        xylostosidine                                                                                                              Lj
  35[\*](#t001fn002){ref-type="table-fn"}   14.11    \[M+Na\]^+^    C~33~H~40~O~18~         747.2125        747.2112          1.7          377.0778, 585.1559, 553.1147, 535.1148, 411.1322, 393.070, 231.1102, 199.0407, 215.0157;   jasmigeniposide A                                                                                                          Gj
  36                                        14.22    \[M+Na\]^+^    C~19~H~30~O~11~         457.1685        457.1686          -0.1         295.1157, 277.1054, 263.0895;                                                              secologanin dimethyl acetal                                                                                                Lj
  37[\*](#t001fn002){ref-type="table-fn"}   14.26    \[M+Na\]^+^    C~34~H~46~O~19~         781.2532        781.2531          0.1          619.2036, 549.1576, 517.1330, 387.1042, 355.0804;                                          *(Z)*-aldosecologanin                                                                                                      Lj
  38                                        14.35    \[M+H\]^+^     C~25~H~28~O~12~         521.1658        521.1659          -0.1         375.1294, 213.0764, 195.0659;                                                              2′-*O*-p-hydroxybenzoyl gardoside                                                                                          Gj
  39                                        14.58    \[M+Na\]^+^    C~32~H~40~O~17~         719.2181        719.2163          2.5          511.1414, 493.1324, 209.0816;                                                              6″-*O*-*trans*-*p*-coumaroylgenipin gentiobioside                                                                          Gj
  40[\*](#t001fn002){ref-type="table-fn"}   14.75    \[M+Na\]^+^    C~34~H~44~O~19~         779.2378        779.2374          0.5          571.1626, 553.1534, 209.0830;                                                              6″-*O*-*trans*-sinapoylgenipin gentiobioside                                                                               Gj
  41[\*](#t001fn002){ref-type="table-fn"}   14.84    \[M+Na\]^+^    C~34~H~46~O~19~         781.2533        781.2531          0.3          619.2133, 549.1332, 517.1320, 387.1041, 355.0841;                                          *(E)*-aldosecologanin                                                                                                      Lj
  42[\*](#t001fn002){ref-type="table-fn"}   14.97    \[M+Na\]^+^    C~33~H~42~O~18~         749.2266        749.2269          -0.4         541.1472, 523.1427, 209.0824;                                                              6″-*O-trans-p*-feruloylgenipin gentiobioside                                                                               Gj
  43                                        16.33    \[M+Na\]^+^    C~28~H~34~O~14~         617.1845        617.1846          -0.2         411.1267, 249.0801, 231.0639, 199.0382;                                                    6′-*O*-*trans*-sinapoylgeniposide                                                                                          Gj
  44[\*](#t001fn002){ref-type="table-fn"}   18.04    \[M+H\]^+^     C~25~H~31~NO~10~        506.2032        506.2026          1.2          344.1493, 326.1419, 298.1437, 274.1083, 256.1046, 228.6037;                                L-phenylalanino secologanin B                                                                                              Lj
  45[\*](#t001fn002){ref-type="table-fn"}   18.45    \[M+Na\]^+^    C~32~H~40~O~16~         703.2203        703.2214          -1.6         495.1643, 477.1374, 209.0827;                                                              6″-*O*-*trans*-cinnamoylgenipin gentiobioside                                                                              Gj
  46                                        1.77     \[M-H\]^-^     C~7~H~12~O~6~           191.0561        191.0556          2.6          173.0466, 137.0236, 129.0551;                                                              quinic acid                                                                                                                Lj/Gj
  47[\*](#t001fn002){ref-type="table-fn"}   7.95     \[M-H\]^-^     C~16~H~18~O~9~          353.0876        353.0873          0.8          191.0559; 179.0439; 129.0553, 161.0235, 135.0452;                                          5-*O*-caffeoylquinic acid                                                                                                  Lj/Gj/Aa
  48                                        9.00     \[M-H\]^-^     C~7~H~6~O~3~            137.0238        137.0239          -0.7         Overlapped in MS^E^ chromatogram                                                           salicylic acid                                                                                                             Lj/Gj/Aa
  49[\*](#t001fn002){ref-type="table-fn"}   9.23     \[M-H\]^-^     C~16~H~18~O~9~          353.0879        353.0873          1.7          191.0560, 179.0357, 173.0469,161.0265, 135.0458;                                           3-*O*-caffeoylquinic acid                                                                                                  Lj/Gj/Aa
  50[\*](#t001fn002){ref-type="table-fn"}   9.54     \[M-H\]^-^     C~16~H~18~O~9~          353.0875        353.0873          0.6          191.0561, 179.0352, 173.0454, 161.0217, 135.0450;                                          4-*O*-caffeoylquinic acid                                                                                                  Lj/Gj/Aa
  51[\*](#t001fn002){ref-type="table-fn"}   9.72     \[M-H\]^-^     C~17~H~20~O~9~          367.1036        367.1029          1.9          353.0876, 191.0549, 179.0380, 173.0411, 161.0265, 135.0424;                                5-*O*-caffeoylquinic methyl ester                                                                                          Lj/Gj/Aa
  52[\*](#t001fn002){ref-type="table-fn"}   10.12    \[M-H\]^-^     C~9~H~8~O~4~            179.0345        179.0344          0.3          135.0445;                                                                                  *trans*-caffeic acid                                                                                                       Lj/Gj
  53[\*](#t001fn002){ref-type="table-fn"}   10.33    \[M-H\]^-^     C~17~H~20~O~9~          367.1046        367.1029          4.6          353.0786, 191.0527, 179.0388, 173.0450, 161.0259, 135.0468;                                3-*O*-caffeoylquinic methyl ester                                                                                          Lj/Gj/Aa
  54                                        10.81    \[M+H\]^+^     C~10~H~12~O~4~          197.0813        197.0814          -0.5         Overlapped in MS^E^ chromatogram                                                           3-hydroxy-4-methoxy styrene acrylic acid                                                                                   Lj/Gj
  55[\*](#t001fn002){ref-type="table-fn"}   11.26    \[M-H\]^-^     C~17~H~20~O~9~          367.1042        367.1029          3.5          353.0871, 191.0565, 179.0366, 173.0456, 161.0313; 135.0445;                                4-*O*-caffeoylquinic methyl ester                                                                                          Lj/Gj
  56                                        11.47    \[M+H\]^+^     C~9~H~8~O~3~            165.0547        165.0552          -3.0         Overlapped in MS^E^ chromatogram                                                           *trans*-p-hydroxycinnamic acid                                                                                             Lj/Gj
  57                                        11.94    \[M-H\]^-^     C~16~H~16~O~8~          335.0768        335.0767          1.0          179.0353;                                                                                  3-*O*-caffeoylshikimic acid                                                                                                Gj
  58[\*](#t001fn002){ref-type="table-fn"}   12.21    \[M+H\]^+^     C~9~H~8~O~2~            149.0604        149.0603          0.7          Overlapped in MS^E^ chromatogram                                                           *trans*-cinnamic acid                                                                                                      Lj
  59                                        13.25    \[M-H\]^-^     C~9~H~10~O~4~           181.0500        181.0501          -0.3         Overlapped in MS^E^ chromatogram                                                           syringaldehyde                                                                                                             Gj/Aa
  60[\*](#t001fn002){ref-type="table-fn"}   13.33    \[M-H\]^-^     C~25~H~24~O~12~         515.1201        515.1190          2.1          353.0887, 191.0567, 179.0357, 173.0456, 161.0255, 135.0455;                                3,4-di-*O*-caffeoylquinic acid                                                                                             Lj/Gj
  61[\*](#t001fn002){ref-type="table-fn"}   13.68    \[M-H\]^-^     C~25~H~24~O~12~         515.1190        515.1190          0            353.0875, 191.0561, 179.0349, 173.0446, 161.0266, 135.0454;                                3,5-di-*O*-caffeoylquinic acid                                                                                             Lj/Gj
  62[\*](#t001fn002){ref-type="table-fn"}   14.35    \[M-H\]^-^     C~25~H~24~O~12~         515,1197        515.1190          1.4          353.0881, 191.0562, 179.0356, 173.0455, 161.0251, 135.0455;                                4,5-di-*O*-caffeoylquinic acid                                                                                             Lj/Gj
  63[\*](#t001fn002){ref-type="table-fn"}   15.29    \[M-H\]^-^     C~26~H~26~O~12~         529.1360        529.1346          2.6          367.1013, 349.0910, 179.0375, 161.0289, 135.0448;                                          3,4-di-O-caffeoylquinic methyl ester                                                                                       Lj/Gj
  64[\*](#t001fn002){ref-type="table-fn"}   15.62    \[M-H\]^-^     C~26~H~26~O~12~         529.1361        529.1346          2.8          367.1048, 349.0920, 179.0344, 161.0319, 135.0466;                                          3,5-di-*O*-caffeoylquinic methyl ester                                                                                     Lj/Gj
  65                                        15.67    \[M-H\]^-^     C~10~H~10~O~4~          193.0500        193.0501          -0.7         Overlapped in MS^E^ chromatogram                                                           *trans*-ferulic acid                                                                                                       Lj/Gj/Aa
  66[\*](#t001fn002){ref-type="table-fn"}   15.80    \[M-H\]^-^     C~26~H~26~O~12~         529.1356        529.1346          1.9          367.1040, 349.0918, 179.0352, 161.0326, 135.0434;                                          4,5-di-*O*-caffeoylquinic methyl ester                                                                                     Lj/Gj
  67                                        12.10    \[M-H\]^-^     C~27~H~30~O~16~         609.1461        609.1456          0.8          301.0346, 283.0244, 181.0138;                                                              rutin                                                                                                                      Lj/Gj
  68                                        12.53    \[M-H\]^-^     C~21~H~20~O~12~         463.0880        463.0877          0.6          301.0347, 181.0140;                                                                        hyperoside                                                                                                                 Lj/Gj
  69                                        12.67    \[M-H\]^-^     C~27~H~30~O~15~         593.1501        593.1506          -0.8         447.0928, 285.0398;                                                                        lonicerin                                                                                                                  Lj/Gj
  70[\*](#t001fn002){ref-type="table-fn"}   12.76    \[M-H\]^-^     C~21~H~20~O~11~         447.0933        447.0927          1.3          285.0399, 165.0197;                                                                        luteolin-7-*O*-β-[d]{.smallcaps}-glucoside                                                                                 Lj/Gj
  71                                        12.77    \[M-H\]^-^     C~15~H~12~O~6~          287.0556        287.0556          0            125.0238;                                                                                  eriodictyol                                                                                                                Lj
  72                                        13.59    \[M-H\]^-^     C~20~H~20~O~8~          387.1086        387.1080          1.5          236.0686;                                                                                  artemetin                                                                                                                  Aa
  73[\*](#t001fn002){ref-type="table-fn"}   17.53    \[M-H\]^-^     C~15~H~10~O~6~          285.0402        285.0399          1.0          267.0295, 239.0344, 165.0195;                                                              luteolin                                                                                                                   Gj
  74[\*](#t001fn002){ref-type="table-fn"}   17.63    \[M-H\]^-^     C~15~H~10~O~7~          301.0350        301.0348          0.2          283.0245, 255.0295, 181.0140, 155.0346;                                                    quercetin                                                                                                                  Lj/Gj/Aa
  75                                        20.00    \[M-H\]^-^     C~18~H~16~O~8~          359.0765        359.0767          -0.5         208.0371;                                                                                  eupatin                                                                                                                    Aa/Gj
  76                                        11.88    \[M-H\]^-^     C~28~H~38~O~13~         581.2239        581.2234          0.9          419.1705, 387.1443, 355.1183;                                                              lyoniresinol-9-*O*-β-[d]{.smallcaps}-glucopyranoside                                                                       Gj
  77                                        13.01    \[M-H\]^-^     C~22~H~28~O~8~          419.1700        419.1706          -1.4         387.1448, 355.1184;                                                                        lyoniresinol                                                                                                               GJ/Lj
  78[\*](#t001fn002){ref-type="table-fn"}   13.11    \[M+Na\]^+^    C~20~H~26~O~7~          401.1581        401.1576          1.2          Identified by standard compound                                                            threo-1-(4-hydroxy-3-methoxyphenyl)-2-\[2-hydroxy-4-(3-hydroxypropyl) phenoxy\]-1,3-propanediol                            Aa
  79[\*](#t001fn002){ref-type="table-fn"}   13.40    \[M+Na\]^+^    C~20~H~26~O~7~          401.1590        401.1576          3.5          Identified by standard compound                                                            erythro-1-(4-hydroxy-3-methoxyphenyl)-2-\[2-hydroxy-4-(3-hydroxypropyl) phenoxy\]-1,3-propanediol                          Aa
  80                                        15.51    \[M+H\]^+^     C~21~H~26~O~7~          391.1700        391.1757          3.3          359.1496;                                                                                  3,3′,5-trimethoxy-4′,7-epoxy-8,5′-neolignan-4,9,9′-triol                                                                   Lj
  81                                        16.18    \[M-H\]^-^     C~20~H~24~O~6~          359.1512        359.1495          4.8          327.1233;                                                                                  dihydrodehydrodiconiferyl alcohol                                                                                          Lj
  82                                        16.64    \[M-H\]^-^     C~20~H~20~O~6~          355.1183        355.1182          0.3          Identified by standard compound                                                            balanophonin                                                                                                               Gj
  83                                        12.81    \[M-H\]^-^     C~21~H~34~O~9~          429.2121        429.2125          -0.9         267.1596, 249.1490, 231.1383;                                                              (1*R*,7*R*,8*S*,10*R*)-7,8,11-trihydroxyguai-4-en-3-one 8-*O*-β*-* [d-]{.smallcaps}glucopyranoside                         Gj
  84[\*](#t001fn002){ref-type="table-fn"}   17.46    \[M+Na\]^+^    C~15~H~20~O~4~          287.1247        287.1259          -4.2         243.1362;                                                                                  *Z-*abscisic acid                                                                                                          Lj
  85[\*](#t001fn002){ref-type="table-fn"}   17.66    \[M+Na\]^+^    C~15~H~20~O~4~          287.1250        287.1259          -3.1         243.1363;                                                                                  *E-*abscisic acid                                                                                                          Lj
  86[\*](#t001fn002){ref-type="table-fn"}   19.02    \[M-H\]^-^     C~15~H~22~O~5~          281.1394        281.1389          1.8          237.1490, 193.1590;                                                                        (1*S*,6*R*,7*R*,10*R*)-6-carboxy-10-methyl-α-methylene-1-(1-oxobutyl)- cyclohexaneacetic acid                              Aa
  87                                        12.74    \[M+H\]^+^     C~10~H~8~O~4~           193.0509        193.0501          4.1          165.0554, 139.0394;                                                                        scopoletin                                                                                                                 Gj/Aa
  88[\*](#t001fn002){ref-type="table-fn"}   13.15    \[M+H\]^+^     C~11~H~10~O~5~          223.0609        223.0606          1.3          195.0656, 169.0500;                                                                        7-hydroxy-6,8-dimethoxyphenyl coumarin                                                                                     Aa
  89[\*](#t001fn002){ref-type="table-fn"}   14.58    \[M+H\]^+^     C~9~H~6~O~2~            147.0447        147.0446          0.7          119.0498, 96.0342;                                                                         coumarin                                                                                                                   Gj
  90[\*](#t001fn002){ref-type="table-fn"}   15.82    \[M-H\]^-^     C~21~H~34~O~11~         461.2019        461.2023          -0.9         329.1602, 167.1070, 123.1177;                                                              (2*E*,6*S*)-8-\[α-L-arabinopyranosyl-(1\"-6\')-β-[d]{.smallcaps}-glucopyranosyloxy\]-2, 6-dimethylct-2-eno-1,2\"-lactone   Lj

^a^ *Gardenia jasminoides* Ellis, *Lonicera japonica* Thunb. and *Artemisia annua* are abbreviated as Gj, Lj and Aa, respectively;

\* This compounds were identified by standard compounds;

3.4.1. Iridoids {#sec011}
---------------

Iridoids are the main constituents of RDN. This category of compounds was primarily derived from *L*. *japonica* and *G*. *jasminoides*. In this study, 45 iridoids were identified in positive ion mode. Four of the iridoids were new compounds, which were previously isolated and identified using NMR \[[@pone.0121031.ref021]\]. The diagnostic fragment ions of these compounds were previously reported \[[@pone.0121031.ref022]--[@pone.0121031.ref024]\]. Such fragments include the neutral cleavage of the glycosidic bond with the neutral loss of a glucose unit (162 Da) and subsequent losses of H~2~O, CO and CH~3~OH. As shown in ([S2 Fig](#pone.0121031.s002){ref-type="supplementary-material"}), 32 peaks appearing in EIC mode were considered as target compounds by extracting the diagnostic ions 209.0814, 251.0532, 235.0582 and 215.0320 with the high-energy MS^E^ function. The proposed fragmentation pathways of typical compounds are discussed in detail below.

Compounds **39**, **40**, **42** and **45** were unambiguously identified as 6″-*O*-*trans*-*p*-coumaroylgenipin gentiobioside, 6″-*O*-*trans*-sinapoylgenipin gentiobioside, 6″-*O-trans-*feruloylgenipin gentiobioside and 6″-*O*-*trans*-cinnamoylgenipin gentiobioside, respectively, by comparing their retention times with authentic reference substances isolated from RDN and fragmentation pathways observed in the MS/MS experiments. Of these, compound **42** was new. Interestingly, we discovered that the MS/MS spectra of their \[M+Na\]^+^ adducts showed base peaks at *m/z* 511.1414 (C~21~H~28~O~13~Na), 571.1626 (C~23~H~32~O~15~Na), 541.1472 (C~22~H~30~O~14~Na) and 495.1643 (C~21~H~28~O~12~Na), respectively. All of these peaks were produced by the loss of a C~11~H~12~O~4~ fragment ([Fig 3](#pone.0121031.g003){ref-type="fig"}). This fragmentation pathway is different from that of iridoid glycosides in which the C6-C3 unit is not substituted onto the C-6 position of the glucose unit. We presumed that the C6-C3 unit, an electron-donating group, might have led to this phenomenon. This mechanism should be further investigated.

![MS/MS spectra and proposed fragmentation pathways of compounds 39, 40, 42 and 45.](pone.0121031.g003){#pone.0121031.g003}

Compound **44** showed a \[M+H\]^+^ ion at *m/z* 506.2032 with an elemental composition of C~25~H~32~NO~10~. The MS/MS spectrum of \[M+H\]^+^ exhibited an obvious fragment ion, \[M+H-Glc\]^+^, at *m/z* 344.1493 (C~19~H~22~NO~5~) from the loss of a neutral glucose residue (162 Da). The base peak at *m/z* 274.1083 (C~15~H~16~NO~4~) was formed by a retro-Diels-Alder (RDA) cleavage reaction in the aglycone moiety. This precursor ion (C~15~H~16~NO~4~) further produced two characteristic fragment ions at *m/z* 256.1046 (C~15~H~14~NO~3~) and 228.1037 (C~14~H~14~NO~2~) through the loss of one H~2~O and the further loss of one CO, respectively. Moreover, two characteristic fragment ions at *m/z* 326.1419 (C~19~H~20~NO~4~) and 298.1437 (C~18~H~20~NO~3~) were formed from \[M+H-Glc\]^+^ by the successive losses of H~2~O and CO. Thus, compound **44** could be tentatively identified as L-phenylalaninosecologanin B ([Fig 4](#pone.0121031.g004){ref-type="fig"}), which was further confirmed by comparison to a reference standard.

![MS/MS spectra and proposed fragmentation pathways of compound 44.](pone.0121031.g004){#pone.0121031.g004}

Compounds **37** and **41** gave the same molecular formula of C~34~H~46~O~19~ from their precursor \[M+Na\]^+^ ions at *m/z* 781.2515 and 781.2533, respectively. In (Fig [5a](#pone.0121031.g005){ref-type="fig"} and [5b](#pone.0121031.g005){ref-type="fig"}) illustrated the positive ion mode MS/MS spectra of compounds **37** and **41** at 35 eV and 42 eV trap collision energy, respectively. Their diagnostic fragmentation ions demonstrated minor differences with the exception for their peak intensity. For example, in compound **37**, a predominant \[M+Na\]^+^ ion was observed at *m/z* 781.2515 (C~34~H~46~O~19~Na, 781.1531, 2.0 ppm). An obvious fragment ion \[M+Na-Glc\]^+^ at *m/z* 619.2036 was observed by the neutral loss of 162 Da. The additional loss of CH~3~OH (32 Da) produced \[M+Na-Glc-CH~3~OH\]^+^ at *m/z* 587.1668. The second predominant peak at *m/z* 549.1576 (C~24~H~30~O~13~Na) was formed through an retro-Diels-Alder (RDA) reaction with the neutral loss of C~4~H~6~O. The fragment ion at *m/z* 517.1330 was formed by successive loss of another CH~3~OH molecule from the ion at *m/z* 549.1576. A minor peak at *m/z* 387.1042 (C~17~H~23~O~10~) was formed by the cleavage of another C~17~H~24~O~9~ fragment. Further loss of CH~3~OH (32 Da) from 387.1042 (C~17~H~23~O~10~) produced *m/z* 355.0804 (C~16~H~19~O~9~). Thus, compound **37** was tentatively identified as (*E*)-aldosecologanin. Compounds **37** and **41** were further confirmed to be (*E*)-aldosecologanin and (*Z*)-aldosecologanin, respectively, based on comparing their retention times with the isolated compounds and fragmentation pathways observed in our MS/MS experiments.

![MS/MS spectra of compounds 37 (a) and 41 (b) and proposed fragmentation pathways of compound 37.](pone.0121031.g005){#pone.0121031.g005}

The \[M+Na\]^+^ ion of compound **35** was observed at *m/z* 747.2114, indicating an elemental composition of C~33~H~40~O~18~Na (747.2115, 0.1 ppm). The MS/MS spectrum of \[M+Na\]^+^ showed a base peak at *m/z* 377.0778 (C~16~H~18~O~9~Na) produced by cleavage of the C~17~H~22~O~9~ fragment. In addition, neutral loss of a glucose unit (162 Da) generated the \[M+Na-Glc\]^+^ at *m/z* 585.1559. Successive losses of CH~3~OH and H~2~O molecules formed \[M+Na-Glc-CH~3~OH\]^+^ at *m/z* 553.1147 and \[M+Na-Glc-CH~3~OH-H~2~O\]^+^ at *m/z* 535.1448. Loss of the C~16~H~16~O~8~ fragment produced \[M+Na-C~16~H~16~O~8~\]^+^ at *m/z* 411.1322 (C~17~H~24~O~10~Na), and successive loss of another H~2~O molecule from 411.1322 led to the formation of an obvious ion at *m/z* 393.0970. The fragment ion at *m/z* 231.1102 (C~11~H~12~O~4~Na) was produced by neutral loss of a glucose unit (162 Da). Other characteristic fragment ions were formed, such as *m/z* 215.0157 and 199.0407, by successive or simultaneous losses of an O atom and a CH~3~OH molecule from *m/z* 231.1102 ([Fig 6](#pone.0121031.g006){ref-type="fig"}). Thus, compound **35** was identified as jasmigeniposide A, which was a new compound isolated from RDN. This result was further confirmed through reference standard comparison.

![MS/MS spectra of compound 35 and proposed fragmentation pathways of compound 35.](pone.0121031.g006){#pone.0121031.g006}

In addition to the above compounds, 37 iridoid glycosides (compounds **1--34**, **36**, **38** and **43**) were identified or tentatively characterized from RDN ([Table 1](#pone.0121031.t001){ref-type="table"}) based on their molecular weights and the tandem fragmentation patterns.

3.4.2. Organic acids {#sec012}
--------------------

According to previous research, caffeoylquinic acids as the main bioactive components in RDN were found in *L*. *japonica* Thunb., *G*. *jasminoides* Ellis and *A*. *annua* L. The structures of these typical constituents generally consist of a quinic acid moiety and mono- or dicaffeic acids that are linked to the 3-OH and/or 4-OH and/or 5-OH \[[@pone.0121031.ref022]\]. These compounds exhibit common proposed fragmentation pathways and diagnostic fragmentation ions, such as *m/z* 353, 191, 179, 173, 135, etc. The differences in the diagnostic fragmentation ion intensity could be used to identify their structures. As shown in ([Fig 1](#pone.0121031.g001){ref-type="fig"}), 15 peaks, including 14 caffeoylquinic acids and one caffeoylquinic substituted new iridoid glycoside, appeared in EIC mode and were considered as target compounds by extracting diagnostic ions 191.0556 and 179.0340 in the high-energy MS^E^ function.

Six peaks were easily located in the chromatogram of RDN by extracting *m/z* 353.0873. Similarly, three parent ions at *m/z* 515.1190 were located. By comparison with accurate retention times, the first three ions were assigned as monocaffeic acids, while the latter three were identified as dicaffeic acids ([Fig 7](#pone.0121031.g007){ref-type="fig"}). According to the literature \[[@pone.0121031.ref025]--[@pone.0121031.ref027]\], the linkage position of the caffeoyl groups on quinic acid could be determined according to its MS^2^ fragmentation behavior. Briefly, when the caffeoyl group was linked to 3-OH or 5-OH, the \[quinic acid-H\]^-^ ion at *m/z* 191 was the base peak, and the \[caffeic acid-H\]^-^ ion at *m/z* 179 was more significant for 3-*O*-caffeoylquinic acids. The \[quinic acid-H~2~O-H\]^-^ ion at *m/z* 173 was the prominent peak when the caffeoyl group was linked to 4-OH. In our experiment, this fragmentation behavior was also observed in the negative mode MS^E^ spectra. Thus, compounds **47**, **49** and **50** were identified as 5-*O*-caffeoylquinic acid, 3-*O*-caffeoylquinic acid and 4-*O*-caffeoylquinic acid, respectively. Similarly, compounds **51**, **53** and **55** were identified as 5-*O*-caffeoylquinic methyl ester, 3-*O*-caffeoylquinic methyl ester and 4-*O*-caffeoylquinic methyl ester, respectively.

![EIC-MS peaks of all possible caffeoylquinic acids in Re-Du-Ning injection.](pone.0121031.g007){#pone.0121031.g007}

Compound **61** had a base peak ion at *m/z* 191.0561 and a secondary peak at *m/z* 179.0349. As reviewed above, **61** could be identified as a 3-substituted quinic acid. Therefore, peak 18 was identified as 3,5-di-*O*-caffeoylquinic acid, which was further confirmed by comparison to a reference standard. Compounds **60** and **62** both produced a base peak at *m/z* 173, indicating that they were both 4-substituted quinic acids. According to literature \[[@pone.0121031.ref028]\], the retention time of 3,4-di-*O*-caffeoylquinic acid is shorter than that of 4,5-di-*O*-caffeoylquinic acid, and thus, the compounds were identified as 3,4-di-*O*-caffeoylquinic acid and 4,5-di-*O*-caffeoylquinic acid, respectively. These retention times were consistent with those of the separate compounds. In addition, compounds **63**, **64** and **66** were identified as 3,4-di-*O*-caffeoylquinic methyl ester, 3,5-di-*O*-caffeoylquinic methyl ester and 4,5-di-*O*-caffeoylquinic methyl ester, respectively.

Compound **46** was identified as quinic acid by comparison with a standard compound. Compounds **54, 57** and **59** were tentatively assigned as 3-hydroxy-4-methoxy styrene acrylic acid, 3-*O*-caffeoylshikimic acid and syringaldehyde, respectively, by matching their accurate molecular weights with those in a chemical database. These assignments were further corroborated by comparison with standard substances. Compounds **48**, **52**, **56**, **58** and **66** were identified by comparison with isolated compounds from RDN (as listed in [Table 1](#pone.0121031.t001){ref-type="table"}).

3.4.3. Flavonoids {#sec013}
-----------------

The MS/MS behaviors of flavonoids and their glycosides have been extensively described \[[@pone.0121031.ref022], [@pone.0121031.ref029]--[@pone.0121031.ref031]\]. Briefly, the primary MS/MS behavior of aglycones was described by the RDA fragmentation pathway. Successive loss of CO from the ketone group, C-fragmentation and loss of radicals, such as CH~3~ and CHO, have been described. For flavonoid glycosides, the glycosidic bond is easily cleaved in positive ion mode, and the neutral loss of 162 Da is the characteristic fragment ion of flavonoid *O*-glycosides. The fragment ion at \[M+H-308\]^+^ corresponds to the loss of a rutinose unit.

As shown in [Table 1](#pone.0121031.t001){ref-type="table"}, a total of nine flavonoids were screened from RDN, four of which were unambiguously identified as rutin (**67**), hyperoside (**68**), luteolin-7-*O*-β-[d]{.smallcaps}-glucoside (**70**), luteolin (**73**) and quercetin (**74**) by comparison with standard constituents isolated from RDN. The other four flavonoids were tentatively identified as lonicerin (**69**), eriodictyol (**71**), artemetin (**72**) and eupatin (**75**) by matching their extract molecular weights with the chemical database and MS/MS fragmentation behavior.

3.4.4. Identification of other compounds {#sec014}
----------------------------------------

Another 15 obvious peaks in the extracted ion chromatogram of RDN were identified ([Table 1](#pone.0121031.t001){ref-type="table"}). Three coumarins, compounds **87**, **88** and **89**, were unambiguously identified as scopoletin, 7-hydroxy-6,8-dimethoxyphenyl coumarin and coumarin, respectively, by comparison with the isolated reference standards. Among the four sesquiterpenes, compound **83** was tentatively assigned as 7,8,11-trihydroxyguai-4-en-3-one 8-*O*-β-[d]{.smallcaps}-glucopyranoside by matching its mass with the chemical database within 5 ppm. Compounds **84**, **85** and **86** were confirmed by matching to the retention times of the isolated reference standards. Similarly, seven lignans (compounds **76**, **77**, **78**, **79**, **80**, **81** and **82**) and one monoterpene (compound **90**) were also identified.

Conclusion {#sec015}
----------

In this work, an approach involving UPLC-ESI-Q/TOF-MS coupled with MS^E^ data acquisition was developed to profile multiple chemical constituents in RDN. Diagnostic ions were used as invaluable markers for the screening of target compounds. A total of 53 compounds, including two new iridoids, were identified or tentatively characterized using this method. Due to the structural complexity of the chemical constituent types in TCMPs, the present analytical approach still has a limitation in the detection of low-abundance components. The remaining 37 compounds were identified according to their accurate mass measurements within 5 ppm error, tandem MS behaviors, database-matching and reference standards. The RDN herbal sources were unambiguously confirmed by comparing the extracted ion chromatograms (EICs) of RDN and ingredient herbal extracts. The results of our study not only provide a certain foundation for further studies of RDN but also demonstrate chemical profile analyses of TCMPs via UPLC-ESI-Q/TOF-MS and diagnostic ion screening using MS^E^.

Supporting Information {#sec016}
======================

###### Total ion chromatograms (TIC) of three different types of 50 mm columns.
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###### MS chromatograms of diagnostic ions:
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